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Abstract
Background: The CIP2A protein is a recently characterized oncoprotein which inhibits protein phosphatase 2A
activity. Expression of CIP2A has been detected in several carcinomas, but its expression and significance in
prostate cancer has not been examined so far.
Methods: Expression of the CIP2A protein was studied using immunohistochemistry in prostate cancer (n = 59)
and in benign prostatic hyperplasia (n = 20) specimens. The CIP2A staining scores were compared with several
clinicopathological parameters.
Results: Expression of CIP2A was increased in prostate cancer epithelium as compared with the benign
hyperplastic epithelium (p < 0.001). The expression of CIP2A was associated with high Gleason scores (p < 0.001)
and among patients treated with radical prostatectomy, CIP2A expression was associated with pre-treatment risk
stratification (p = 0.011) and pathological T-class (p = 0.031). No statistically significant association was detected
between CIP2A expression and prostate specific antigen concentrations.
Conclusions: Expression of the CIP2A protein is increased in prostate cancer specimens and its expression is
associated with poorly differentiated and high-risk tumors.
Background
Serine/threonine protein phosphatase 2A (PP2A) is a
tumor suppressor that plays an integral role in the regula-
tion of a number of major signaling pathways which can
contribute to carcinogenesis [1]. The cellular inhibitor of
PP2A, named CIP2A (and also known as KIAA1524 and
p90 tumor-associated antigen), is a recently identified
human oncoprotein which promotes MYC protein stabi-
lity by inhibiting PP2A-mediated dephosphorylation of
MYC [2]. An increased expression of CIP2A has been
detected in gastric [3,4], breast [5] and colon adenocarci-
nomas and in head and neck squamous cell carcinomas
[2]. Interestingly, auto-antibodies against CIP2A were
detected in over 30% of sera from prostate adenocarci-
noma patients while only 1.5% of benign prostatic hyper-
plasia (BPH) patients were found to be positive for these
antibodies [6].
The aim of this study was to investigate expression of
the CIP2A protein in prostate cancer specimens and in
BPH samples, and to examine whether CIP2A immuno-
positivity is associated with clinicopathological para-
meters in these patients.
Methods
Patient samples
Archived prostate specimens were initially collected
from patients that underwent prostatectomy or transur-
ethral resection of prostate as the treatment for prostate
cancer or BPH at the Oulu University Hospital. The
material consisted of 59 prostate cancer and 20 BPH tis-
sue specimens, including radical prostatectomy speci-
mens from cancer patients (n = 31), occult carcinomas
diagnosed after transurethral resection for symptoms of
BPH (n = 13) and palliative transurethral resections
from prostate cancer patients who underwent castration
t h e r a p y( n=1 5 ) .T h e r ew e r e1 ,1 3 ,7 ,1 5 ,1 ,1 3a n d9
prostate tumors with Gleason scores of 4, 5, 6, 7, 8, 9
and 10, respectively. Information about corresponding
Gleason scores, disease stages and prostate-specific anti-
gen (PSA)-concentrations preceding tissue sampling
were obtained from patient records. The Ethics Council
of The Northern Ostrobothnia Hospital District
approved the research plan.
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Paraffin-embedded blocks were cut into sections of 4 μm
in thickness and mounted on pre-coated slides. The sec-
tions were then deparaffinized in xylene and rehydrated
in a descending ethanol series. In order to enhance
immunoreactivity, the sections were incubated in TRIS-
E D T A ,p H9 . 0 ,a n db o i l e df o r1 5m i n .E n d o g e n o u sp e r -
oxidase activity was eliminated by incubation in hydrogen
peroxide and absolute methanol. The antibody used in
the study was a rabbit polyclonal antibody agains human
CIP2A (NB100-74663, Novus Biologicals, Littleton, CO,
USA, dilution 1:400). The bound antibodies were visua-
lized using the Envision Detection System (K500711;
Dako Denmark A/S), and DAB (diaminobenzidine) was
used as a chromogen. Omission of the primary antibody
served as a negative control.
Scoring
The immunopositivity of CIP2A was graded in each
sample based on the intensity of the cytoplasmic immu-
noreactivity in the cancer cells: 3 was strong, 2 moder-
ate, 1 weak, and 0 negative. Using these criteria, the
immunostaining results were evaluated independently by
two observers (MRV and MV). Interobserver correlation
was calculated from the independent evaluations. For
cases with discrepancy, a consensus was reached during
a common evaluation session.
Statistical analyses
Between group comparisons were performed using Fish-
er’s exact test for categorical variables. Continuous vari-
ables were compared with CIP2A staining using the
Student’s t-test or the Mann-Whitney U-test. The intra-
class correlation coefficient (ICC) was calculated for the
two evaluators of CIP2A immunostaining. Two-tailed
p-values are presented and SPSS for Windows 15 (Chi-
cago, IL, USA) was used for statistical analyses.
Results
CIP2A expression is increased in prostate cancer
Expression of the CIP2A protein was studied using immu-
nohistochemistry and archival tissue specimens of prostate
adenocarcinoma (n = 59) and BPH (n = 20). The ICC was
calculated for the two evaluators of CIP2A, was and was
found to be at an acceptable level (ICC = 0.93, 95% confi-
dence interval 0.89 to 0.96). The clinical characteristics of
the prostate cancer patients are presented in Table 1. All
except for two prostate cancer specimens (96.6%) exhib-
ited CIP2A immunopositivity in the prostate adenocarci-
noma cells, but no staining was present in the stroma.
Staining of CIP2A was also detected in epithelial cells of
the hyperplastic epithelium (Figure 1). However, while in
most cancer specimens (73%) the staining pattern was a
coarse granular cytoplasmic positivity of moderate or
strong intensity, the hyperplastic samples only stained
weakly in an almost uniform manner (90%). For further
analysis, CIP2A immunopositivity was divided into nega-
tive (score 0-1) vs. positive (scores 2-3) subgroups. The
staining scores in the benign and malignant prostate speci-
mens are presented in Table 2, which shows that CIP2A
expression was significantly higher in prostate cancer spe-
cimens than in hyperplastic specimens (p < 0.001). In con-
clusion, these results suggest that expression of the CIP2A
protein is increased in the epithelial cell compartments of
prostatic adenocarcinoma.
CIP2A expression is increased in aggressive prostate
tumors
The staining intensity of CIP2A increased with increasing
Gleason score, as the mean Gleason scores for CIP2A-
negative and positive tumors were 5.5 and 8.0, respectively
(p < 0.001). When the tumor specimens were stratified
according to their clinically relevant Gleason scores as low
risk and high risk tumors, there were significantly more
CIP2A-positive cases among tumors with Gleason scores
of 7-10 compared to those with Gleason scores of 6 or less
(Table 3; p < 0.001). We further evaluated the association
between CIP2A staining and pre-treatment clinical pros-
tate cancer risk group stratification based on PSA values,
Gleason scores and clinical tumor staging [7] among
patients treated by radical prostatectomy (n = 31). There
were 2 (28.6%), 10 (62.5%) and 8 (100%) CIP2A-positive
tumors among the low, intermediate and high-risk tumors,
respectively. These data show that CIP2A expression was
less frequent in low-risk tumors than in high-risk tumors
categorized by the pre-treatment risk stratification (p =
0.011). Furthermore, pathological T-class had a positive
association with CIP2A staining intensity, as the propor-
tion of CIP2A-positive tumors was larger among locally
advanced disease samples compared to organ confined
Table 1 Clinical characteristics of the prostate cancer
patients
Gleason score n (%)
4-6 21 (35.6)
7 15 (25.4)
8-10 23 (39.0)
PSA (ng/ml) mean
(SD)
Radical prostatectomy patients (n = 31) 9.1 (5.0)
Other prostate cancer patients (n = 28) 59 (169)
Preoperative risk group n (%)
Low-risk group (cT1a-cT2a, N0, M0 and Gleason score ≤6
and PSA <10 ng/mL)
7 (22.6)
Intermediate-risk group (cT2b or PSA 10-20 ng/mL or
Gleason score 7)
16 (51.6)
High-risk group (cT2c or higher or Gleason score >7 or PSA
>20 ng/mL)
8 (25.8)
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CIP2A staining intensity did not show any association (p =
0.13). There were 6 and 3 patients with biochemical or
clinical progression after radical prostatectomy, with fol-
low-up times of 3-77 and 2-41 months, respectively. Only
one patient who had radical prostatectomy died of pros-
tate cancer. The low number of patients with a progressive
disease did not enable us to evaluate the prognostic role of
CIP2A expression in this material. Taken altogether,
CIP2A staining intensity increased significantly with
increasing Gleason score, increasing pre-treatment clinical
risk group stratification and increasing pathological
T-class after radical prostatectomy, which are all asso-
ciated with aggressive behavior of prostate cancer.
Discussion
In the present study we demonstrated an increased
expression of CIP2A in the human prostate cancer
epithelium as compared with BPH. Furthermore, when
the tumors were stratified according to the Gleason
score, increased CIP2A expression was detected in the
subgroup of high Gleason scores (grades 7-10) when
compared to the lower Gleason scores (grades 6 or
below). In addition, we demonstrated a positive associa-
tion between prostate cancer preoperative risk stratifica-
tion and CIP2A expression, further supporting the
potential prognostic significance of CIP2A in prostate
cancer. The prognostic significance of CIP2A in prostate
cancer needs to be evaluated in a larger cohort with suf-
ficient follow-up times.
The CIP2A protein is expressed in human gastric can-
cer [3,4,8], and it promotes proliferation of gastric cancer
cells [3,4]. It has been assumed that CIP2A facilitates cell
proliferation at least in part by promoting MYC stability.
Furthermore, CIP2A has prognostic significance in cer-
tain subgroups of gastric cancer [4]. The CIP2A protein
also promoted growth of breast cancer xenografts, and
expression of the transcript was found to correlate with
the expression of proliferation markers and p53 muta-
tions, and with lymph node positivity in clinical breast
cancer specimens [5]. In gastric cancer cell lines, induc-
tion of CIP2A expression following Helicobacter pylori
infection was dependent on Src and Ras/mitogen-acti-
vated protein kinase kinase/extracellular signal-regulated
kinase pathways [9]. These pathways are known to play a
role in the acquisition of androgen independence [10,11],
which is the central therapeutic problem in the treatment
of metastasized prostate cancer.
Novel serological markers are required for the diagno-
sis of prostate cancer, and more importantly, to diag-
nose potentially lethal forms of the disease. Auto-
antibodies against CIP2A were detected in 13%, 5% and
3% of the sera of hepatocellular, gastric and esophageal
carcinomas, respectively [8]. Subsequently, similar auto-
antibodies were detected more frequently (30%) in the
sera of prostate cancer patients, while only rarely (1.5%)
in BPH patients. Furthermore, CIP2A auto-antibodies
were present more frequently (29% vs. 16%) in the sera
of prostate cancer patients with a high Gleason score
(seven or higher) when compared to patients with less
aggressive disease [6]. These data with the present
results suggest that evaluation of CIP2A and/or the
auto-antibody concentrations against it may help in the
identification of aggressive prostate cancer.
We studied CIP2A expression by immunohistochemis-
try only, which is a limitation of the present study.
Figure 1 Expression of CIP2A in benign prostatic hyperplasia and in prostate cancer. Immunohistochemical detection of CIP2A protein
expression in benign prostatic hyperplasia specimens (A) and in prostate cancer specimens (B-C). The representative Gleason scores of 6 (B) and
9 (C) are presented. Diffuse, weak cytoplasmic staining of CIP2A was present in hyperplastic tissues, whereas the staining pattern in cancer cells
showed coarsely granular cytoplasmic positivity. Magnification × 100, and in inserts × 400.
Table 2 CIP2A immunostaining intensity in benign
prostatic hyperplasia and prostate cancer
CIP2A immunostaining
n negative positive
Hyperplasia 20 18 (90.0%) 2 (10.0%)
Prostate cancer 59 16 (27.1%) 43 (72.9%)
p < 0.001 (Fisher’s exact test).
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of the functional gene product, CIP2A protein, and
measuring RNA expression levels are not always con-
gruent with those of the protein. To this end, since our
results show significant association of CIP2A protein
expression with relevant clinicopathological variables,
our data are important and suggest a novel link between
the oncogenic CIP2A and carcinogenesis of the prostate.
Conclusions
We showed that expression of the CIP2A protein is
increased in aggressive forms of prostate cancer. Further
studies are required to demonstrate the prognostic role
of CIP2A in prostate cancer and its value in the identifi-
cation of aggressive disease forms.
Acknowledgements
We would like to thank Ms Mirja Vahera and Ms Erja Tomperi for their skilful
technical assistance. Pasi Ohtonen, M.Sc. is acknowledged for his invaluable
assistance with statistical analyses. MHV was supported by the Finnish
Medical Fund.
Author details
1Department of Surgery, Oulu University Hospital, PO Box 21, 90029 OYS,
Finland.
2Department of Pathology, Oulu University Hospital and University
of Oulu, PO Box 50, 90029 OYS, Finland.
3Department of Pathology, HUSLAB
and Haartman Institute, and Genome-Scale Biology Research Program, PO
Box 63, 00014 University of Helsinki, Finland.
Authors’ contributions
MHV and M-RV evaluated the immunostainings. MHV performed the
statistical analysis. MHV and AR drafted the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 September 2010 Accepted: 21 October 2010
Published: 21 October 2010
References
1. Eichhorn PJ, Creyghton MP, Bernards R: Protein phosphatase 2A
regulatory subunits and cancer. Biochim Biophys Acta 2009, 1795:1-15.
2. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-
aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ,
Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J: CIP2A
inhibits PP2A in human malignancies. Cell 2007, 130:51-62.
3. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D: CIP2A is overexpressed
in gastric cancer and its depletion leads to impaired clonogenicity,
senescence, or differentiation of tumor cells. Clin Cancer Res 2008,
14:3722-3728.
4. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M,
Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimaki A: MYC-
dependent regulation and prognostic role of CIP2A in gastric cancer. J
Natl Cancer Inst 2009, 101:793-805.
5. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J,
Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J: CIP2A is
associated with human breast cancer aggressivity. Clin Cancer Res 2009,
15:5092-5100.
6. Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, Daniels T,
Casiano CA, Heeb MJ, Chan EK, Tan EM: Preferential humoral immune
response in prostate cancer to cellular proteins p90 and p62 in a panel
of tumor-associated antigens. Prostate 2005, 63:252-258.
7. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH: Cancer-specific
mortality after surgery or radiation for patients with clinically localized
prostate cancer managed during the prostate-specific antigen era. J Clin
Oncol 2003, 21:2163-2172.
8. Soo Hoo L, Zhang JY, Chan EK: Cloning and characterization of a novel
90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer.
Oncogene 2002, 21:5006-5015.
9. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C, Jia J:
Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src
and MEK/ERK pathways. J Med Microbiol 2010, 59:259-265.
10. Feldman BJ, Feldman D: The development of androgen-independent
prostate cancer. Nat Rev Cancer 2001, 1:34-45.
11. Fizazi K: The role of Src in prostate cancer. Ann Oncol 2007, 18:1765-1773.
doi:10.1186/1756-9966-29-136
Cite this article as: Vaarala et al.: CIP2A expression is increased in
prostate cancer. Journal of Experimental & Clinical Cancer Research 2010
29:136.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Table 3 CIP2A immunostaining intensity in low and high
Gleason score tumors
CIP2A immunostaining
n negative positive
Gleason score 4-6 21 14 (66.7%) 7 (33.3%)
Gleason score 7-10 38 2 (5.3%) 36 (94.7%)
p < 0.001 (Fisher’s exact test).
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